Werewolf Therapeutics Inc. has announced a significant corporate reorganization, with its board of directors approving a reduction in force that will impact 64% of the company's workforce. The move, expected to be substantially completed by February 13, 2026, is aimed at decreasing operating expenses. The company is also exploring strategic alternatives to maximize value for shareholders, including potential partnerships for the further development of its WTX-124 and WTX-330 INDUKINE programs. Werewolf Therapeutics had previously sought to raise capital and engaged in confidential discussions with potential investors regarding its business and pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-051455), on February 13, 2026, and is solely responsible for the information contained therein.